Safety, Tolerability, and Outcomes of Velpatasvir/SofosbuviR in Treatment of Chronic Hepatitis C Virus during Pregnancy (STORC)

1. To evaluate the sustained virologic response 12 weeks after completion of SOF/VEL treatment (SVR12) in women treated during pregnancy.

2. To evaluate impact of antenatal treatment with SOF/VEL on the gestational age at delivery for women who received SOF/VEL for HCV treatment during pregnancy.

Please use this link for further information:

Primary Investigator: John Cafardi